Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds - Eli Lilly (NYS
A California jury awarded Nektar Therapeutics $90M, finding Eli Lilly breached a good faith agreement. The case involved a licensing deal for the drug rezpegaldesleukin. The verdict is not final, pending post-trial proceedings and possible appeals. Nektar's shares rose slightly, while Lilly's fell.
How this was made
The 30-second read
Why it matters
The verdict introduces a new liability for Lilly and a cash award for Nektar, affecting both stocks' short‑term sentiment.
Market read
Legal outcome creates immediate trading opportunities for both firms and underscores litigation risk in biotech licensing.
What to watch
Potential impact on Lilly's ongoing rezpegaldesleukin program and future collaborations.
Background
The lawsuit stemmed from a 2023 licensing agreement for rezpegaldesleukin, a drug under Phase 3 trials for atopic dermatitis.
Ticker impact
Eli Lilly was found to have breached the implied covenant of good faith in its licensing deal with Nektar, resulting in a $90 million jury verdict.
Short-term dip of 1‑2% pending appeal outcome.
The $90 M judgment is a material new liability for a large pharma, likely prompting traders to sell or hedge.
Nektar Therapeutics secured a $90 million judgment against Eli Lilly for breach of covenant in their rezpegaldesleukin licensing agreement.
Potential modest upside of 0.5‑1% as investors price in the award.
The judgment provides a cash infusion but is modest relative to market cap; impact likely limited.
Market effects
Highlights litigation risk in pharma licensing deals.
U.S. biotech sector may see slight volatility.
Limited to investors tracking pharma legal exposures.
Counterpoint
The $90 M award may be appealed successfully, limiting downside for Lilly.
Key entities
- CompanyEli Lilly and Co.
Pharmaceutical company found liable for breach of covenant.
- CompanyNektar Therapeutics Inc.
Biotech firm awarded $90 M in damages.
